Phtalazinone derivatives and manufacturing process thereof

A method of inhibiting the growth of a tumor associated with cancer in a subject, comprising administering an effective amount of a pharmaceutical composition comprising a compound to the subject, wherein the compound is represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof

• In the present Formula I,
• n is 1 or 2,
• R is
• Wherein, when the R is
• m is 0, 1 or 2,
• L is oxygen, methylene, carbonyl, NRc2CO, NRc3, CONRc4 or CH2NRc5(especially, Rc2, Rc3, Rc4 and Rc5 is each independently hydrogen atom, C1-4 alkylamine, C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl or 3-8 membered heterocycle),
• RX is hydrogen, cyano, hydroxyl, trifluoromethyl, C1-6 alkyl or C3-8 cycloalkyl,
• RY is hydrogen, dimethylcarbamoyl, cyano, hydroxyl, trifluoromethyl, halo, ethoxycarbonyl, C1-4 alkylamine, C1-6 alkyl, C1-6 methoxyalkyl or C2-6 alkynyl,
• Z is unsubstituted, C1-6 alkyl, C1-6 methoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C6-10 aromatic cycle or 3-8 membered heterocycle having 1-3 nitrogens,
• wherein, when the R is
• p and q is each independently from 1 to 3,
• W is CRd1Rd2 or NRd3(especially, Rd1, Rd2 and Rd3 is each independently hydrogen, fluoro or C1-6 alkyl),
• wherein, when the R is
• R1, R2 and R3 is each independently hydrogen or C1-6 alkyl.